# TBI Dose De-escalation for Fanconi Anemia

> **NCT00352976** · PHASE2,PHASE3 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 83 (actual)

## Conditions studied

- Fanconi Anemia

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **PROCEDURE:** Total Body Irradiation
- **PROCEDURE:** Bone Marrow Transplantation
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT00352976
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05-18
- **Primary completion:** 2020-10-09
- **Final completion:** 2020-10-09
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2021-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00352976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00352976, "TBI Dose De-escalation for Fanconi Anemia". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00352976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*